Inspiration Biopharmaceuticals Inc

Entity type image
Type: Company
Name: Inspiration Biopharmaceuticals Inc
First reported Mar 22 2013 - Updated Mar 22 2013 - 1 reports
Ipsen SA
Ipsen SA

Ipsen And Inspiration Biopharmaceuticals Announce Closing Of The Sale Of OBI-1 To Baxter International

Sorry, there is a problem with our siteThe page you have requested cannot be displayedThis occurrence has been logged for quality assurance purposes. ... [Published Bioresearch Online - Mar 22 2013]
First reported Mar 14 2013 - Updated Mar 14 2013 - 1 reports

Cangene loses $3.26-million (U.S.) in Q2 fiscal 2013

Cangene Corp. has released its financial results for the second quarter of 2013, which ended on Jan. 31, 2013. (Information and non-IFRS Financial Measures at the end of this release. Unless noted otherwise, all dollar amounts are in U.S. dollars.) Total ... [Published Stockwatch - Mar 14 2013]
First reported Feb 20 2013 - Updated Feb 20 2013 - 1 reports

Cangene closes hemophilia compound acquisition

Cangene Corp. has closed the acquisition of the investigational hemophilia compound IB1001 and certain other assets from Ipsen and Inspiration Biopharmaceuticals Inc. in connection with Inspiration's bankruptcy proceedings. (Unless noted otherwise, all ... [Published Stockwatch - Feb 20 2013]
First reported Feb 11 2013 - Updated Feb 11 2013 - 1 reports
Toronto stock exchange
Toronto stock exchange

Monday Deal Review: February 11, 2013

Welcome to your Monday Biotech Deal Review for February 11, 2013! This week saw YM Biosciences obtain the required court approval necessary before their plan of arrangement acquisition by Gilead could proceed. The transaction is essentially free to ... [Published The Cross-Border Biotech Blog - Feb 11 2013]
First reported Jan 29 2013 - Updated Jan 29 2013 - 1 reports
Baxter International Inc
Baxter International Inc

Baxter to acquire investigational hemophilia compound and related assets

Baxter International has entered into an agreement to acquire Inspiration BioPharmaceuticals' investigational hemophilia compound OBI-1 and related assets. ... [Published PBR - News - Jan 29 2013]
First reported Jan 28 2013 - Updated Jan 28 2013 - 1 reports

Baxter to acquire haemophilia compound, OBI-1 from Inspiration BioPharmaceuticals

Baxter International Inc. has agreed to acquire the investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals, Inc. as well as certain other OBI-1 related assets, including manufacturing operations, from Ipsen Pharma ... [Published PharmaBiz - Jan 28 2013]
First reported Dec 13 2012 - Updated Dec 13 2012 - 1 reports

Pharmacy News

Genervon Established That Its Targeted Drug Benefits ALS Disorder Through 8 Pathways and Modulates over 30 Specific ALS Genes Dynamically PASADENA, Calif.–(BUSINESS WIRE)–Genervon’s GM604 regulates over 4000 genes, modifies ALS disease, modulates 30 ALS ... [Published Rx Times Pharmacy Magazine - Dec 13 2012]

Quotes

"Baxter's global portfolio remains strong as we benefit from our focus on lifesaving therapies, achieve important new product milestones and make select investments to position our company for future success and accelerated growth" said Robert L Parkinson, Jr., chairman and CEO
Baxter Updates on First Quarter Expectations, Confirms Full-. . . [Published Equities.com - Apr 30 2013]
...our net earnings on a year-to-date basis, and by our recent licensing agreements and acquisitions," says John Sedor, President and CEO of Cangene. "We are excited about IB1001, the late-stage intravenous recombinant Factor IX product we acquired in February, as well as our recent licensing agreement for technology to advance a potential treatment for Alzheimer's Disease. We remain focused on adding to our product portfolio to maximize the full potential of our exceptional commercial platform, and to diversify and strengthen our revenue streams. We believe Cangene is on the right path to delivering significant long-term value to shareholders." As at January 31, 2013, Cangene had no debt and a cash balance of $38.7 million, compared with no debt and a cash balance of $35...
Cangene loses $3.26-million (U.S.) in Q2 fiscal 2013 [Published Stockwatch - Mar 14 2013]
"OBI-1 has the potential to address existing unmet needs of hemophilia patients and is a strong strategic fit with Baxter's current haemophilia portfolio" said Bruce Ewenstein, MD, vice president of clinical affairs in Baxter's BioScience business
Baxter to acquire haemophilia compound, OBI-1 from Inspiration BioPharmaceuticals [Published PharmaBiz - Jan 28 2013]
...piration's unique product portfolio have been the basis for a successful collaboration," said John P Butler, chief executive officer of Inspiration. "This new arrangement confirms Ipsen's ongoing commitment to Inspiration, while also enabling Inspiration to become an independent, fully integrated, commercial biopharmaceutical company serving people living with haemophilia."
Ipsen gets IB1001 & OBI-1 commercialization rights from Inspiration in Europe, Russia, China & Au ... [Published PharmaBiz - Aug 22 2012]

More Content

All (39) | News (10) | Reports (1) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (22)
sort by: Date | Relevance
Baxter Updates on First Quarter Expectations, C... [Published Equities.com - Apr 30 2013]
Baxter achieves its first quarter expectations [Published European Pharmaceutical Review - Apr 19 2013]
Baxter International Management Discusses Q1 20... [Published Seeking Alpha - Apr 18 2013]
Baxter Achieves Its First Quarter Expectations ... [Published Equities.com - Apr 18 2013]
Ipsen And Inspiration Biopharmaceuticals Announ... [Published Bioresearch Online - Mar 22 2013]
Ipsen and Inspiration Biopharmaceuticals announ... [Published Business Wire Health News - Mar 21 2013]
Ipsen et Inspiration Biopharmaceuticals annonce... [Published Business Wire Health News - Mar 21 2013]
Inspiration Biopharmaceuticals and Ipsen announ... [Published Business Wire Professional Services News - Mar 21 2013]
Inspiration Biopharmaceuticals and Ipsen announ... [Published Business Wire Health News - Mar 21 2013]
Cangene loses $3.26-million (U.S.) in Q2 fiscal... [Published Stockwatch - Mar 14 2013]
Ipsen's 2012 Results and 2013 Financial Objecti... [Published Yahoo! Finance - Feb 27 2013]
Monday Deal Review: February 25, 2013 [Published The Cross-Border Biotech Blog - Feb 25 2013]
Cangene closes hemophilia compound acquisition [Published Stockwatch - Feb 20 2013]
Inspiration Biopharmaceuticals and Ipsen Announ... [Published EON Health & Medicine - Feb 20 2013]
Inspiration Biopharmaceuticals and Ipsen Announ... [Published Business Wire Health News - Feb 20 2013]
Ipsen and Inspiration Biopharmaceuticals Announ... [Published Business Wire Health News - Feb 20 2013]
Monday Deal Review: February 11, 2013 [Published The Cross-Border Biotech Blog - Feb 11 2013]
DOTW: Biogen Puts Offshore Cash to Work [Published The IN VIVO Blog - Feb 08 2013]
Celtic Pharma Welcomes the Results of the Sale ... [Published EON Health & Medicine - Feb 07 2013]
Celtic Pharma Welcomes the Results of the Sale ... [Published EON Business - Feb 07 2013]
Celtic Pharma Welcomes the Results of the Sale ... [Published Business Wire Health News - Feb 07 2013]
Inspiration Biopharmaceuticals and Ipsen Comple... [Published EON Health & Medicine - Feb 06 2013]
Inspiration Biopharmaceuticals and Ipsen Comple... [Published Business Wire Professional Services News - Feb 06 2013]
Inspiration Biopharmaceuticals and Ipsen Comple... [Published Business Wire Health News - Feb 06 2013]
Ipsen and Inspiration Biopharmaceuticals enter ... [Published Business Wire Health News - Feb 06 2013]
Baxter to acquire investigational hemophilia co... [Published PBR - News - Jan 29 2013]
Baxter to acquire haemophilia compound, OBI-1 f... [Published PharmaBiz - Jan 28 2013]
Deals of the Week Ponders Eleventh-Hour Risk [Published The IN VIVO Blog - Jan 25 2013]
Inspiration Biopharmaceuticals and Ipsen agree ... [Published EON Health & Medicine - Jan 24 2013]
Inspiration Biopharmaceuticals and Ipsen agree ... [Published EON Business - Jan 24 2013]
1 2
In Focus
  •  
Robert L Parkinson, Sten Stovall, George Scangos, [more]
  •  
Ipsen SA, Baxter International Inc, Cangene Corp, [more]
  •  
FDA Food & Drug Administration, University of British Columbia, European Medicines Agency, [more]
  •  
Recombinant, Hemophilia, Porcine, [more]
  •  
Advate, Tysabri, Anti-Inhibitor Coagulant Complex, [more]
  •  
Paris, Boston (Massachusetts, United States), London, [more]
  •  
United States, Bermuda, China, [more]
  •  
Medication, Research & Development, Financial Reporting, [more]
  •  
Banking & Financial Services, Health, Pharma & Biotech
Business Wire Health News, EON Health & Medicine, Business Wire Professional Services News, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Monday Deal Review: February 25, 2013 [Published The Cross-Border Biotech Blog - Feb 25 2013]
Welcome to your Monday Biotech Deal Review for February 25, 2013! This week saw significant activity on the investment front. Stem Cell Therepeutics and Sirona have each indicated an intention to raise funds through private placements, while Oncolytics ...
Monday Deal Review: February 11, 2013 [Published The Cross-Border Biotech Blog - Feb 11 2013]
Welcome to your Monday Biotech Deal Review for February 11, 2013! This week saw YM Biosciences obtain the required court approval necessary before their plan of arrangement acquisition by Gilead could proceed. The transaction is essentially free to ...
DOTW: Biogen Puts Offshore Cash to Work [Published The IN VIVO Blog - Feb 08 2013]
When it comes to corporate tax planning, biopharmas as a group aren’t spectacularly sophisticated. (A few exceptions come to mind, most notably specialty pharma Valeant and Bristol Myers-Squibb, the latter of which upped its game and expects to drop ...
Baxter to acquire investigational hemophilia co... [Published PBR - News - Jan 29 2013]
Baxter International has entered into an agreement to acquire Inspiration BioPharmaceuticals' investigational hemophilia compound OBI-1 and related assets. ...
Deals of the Week Ponders Eleventh-Hour Risk [Published The IN VIVO Blog - Jan 25 2013]
Pharma dealmaking is usually fraught with all kinds of risks, whether technical, clinical, regulatory, financial, or otherwise. But Allergan’s buyout of migraine drug developer MAP Pharmaceuticals this week represented a unique roll of the dice: ...
1 2

Press Releases

sort by: Date | Relevance
Ipsen and Inspiration Biopharmaceuticals announ... [Published Business Wire Health News - Mar 21 2013]
Ipsen et Inspiration Biopharmaceuticals annonce... [Published Business Wire Health News - Mar 21 2013]
Inspiration Biopharmaceuticals and Ipsen announ... [Published Business Wire Professional Services News - Mar 21 2013]
Inspiration Biopharmaceuticals and Ipsen announ... [Published Business Wire Health News - Mar 21 2013]
Inspiration Biopharmaceuticals and Ipsen Announ... [Published EON Health & Medicine - Feb 20 2013]
1 2 3 4 5
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.